Mantle Cell Lymphoma: Current Treatment Practices and Emerging Therapeutic Advances Highlights from the 29th European Hematology Association (EHA) 2024 Congress focusing on the novel treatment modalities available to patients with newly diagnosed or relapsed mantle cell lymphoma DOWNLOAD PDF VERSION Abstract The EHA2024 Hybrid Annual Congress, organized by the European Hematology Association (EHA), was held

Mantle Cell Lymphoma (MCL), characterized by its heterogeneity and challenging prognosis, has seen significant therapeutic advances over the past decade. This summary aims to encapsulate the pivotal discussions from the EHA Congress, providing a comprehensive overview of the current state and future directions in MCL management. From the front lines of first-line treatment to the

Mantle Cell Lymphoma (MCL), characterized by its heterogeneity and challenging prognosis, has seen significant therapeutic advances over the past decade. This summary aims to encapsulate the pivotal discussions from the EHA Congress, providing a comprehensive overview of the current state and future directions in MCL management. From the front lines of first-line treatment to the